Good afternoon and welcome to today's conference call for Omeros Corporation. (Operator Instructions) Please be advised that this call is being recorded at the company's request and a replay will be ...
Let's first discuss our PNH program, which continues advancing rapidly and generating compelling data. Our Phase 2 switchover study evaluated zaltenibart in PNH patients with a suboptimal response to ...